Malignant high-grade glioma (HGG) is the most common and extremely fatal type of
primary intracranial tumor. These tumors recurred within 2 to 3 cm of the primary region of tumor
resection in the majority of cases. Furthermore, the blood-brain barrier significantly limited the access
of many systemically administered chemotherapeutics to the tumor, pointing towards a stringent
need for new therapeutic patterns. Therefore, targeting therapy using local drug delivery for
HGG becomes a priority for the development of novel therapeutic strategies. The main objectives to
the effective use of chemotherapy for HGG include the drug delivery to the tumor region and the infusion
of chemotherapeutic agents into the vascular supply of a tumor directly, which could improve
the pharmacokinetic profile by enhancing drug delivery to the neoplasm tissue. Herein, we reviewed
clinical and molecular features, different methods of chemotherapy application in HGGs, especially
the existing and promising targeting therapies using local drug delivery for HGG which could effectively
inhibit tumor invasion, proliferation and recurrence of HGG to combat the deadly disease.
Undoubtedly, novel chemical medicines targeting these HGG may represent one of the most important
directions in the Neuro-oncology.
Keywords: Glioma, drug delivery, blood-brain barrier, Genetic alterations, chemotherapy, malignant high-grade glioma.
Rights & PermissionsPrintExport